We are live on ! Find out more
CSTL icon

Castle Biosciences

163 hedge funds and large institutions have $1.29B invested in Castle Biosciences in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 45 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more call options, than puts

Call options by funds: $8.19M | Put options by funds: $3.16M

105% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 19

91% more capital invested

Capital invested by funds: $674M → $1.29B (+$617M)

42% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 45

13% more funds holding

Funds holding: 144163 (+19)

12.35% more ownership

Funds ownership: 68.35%80.7% (+12%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
163
Holders Change
+19
Holders Change %
+13.19%
% of All Funds
2.88%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
39
Increased
64
Reduced
45
Closed
19
Calls
$8.19M
Puts
$3.16M
Net Calls
+$5.03M
Net Calls Change
+$5.82M
Name Holding Trade Value Shares
Change
Change in
Stake
JF
176
Jump Financial
Illinois
-$204K -3,970 Closed
Renaissance Technologies
177
Renaissance Technologies
New York
-$201K -3,900 Closed
MAM
178
Meeder Asset Management
Ohio
-$66K -1,294 Closed
CCM
179
Chiron Capital Management
Florida
-$18K -350 Closed
VI
180
Vestcor Inc
New Brunswick, Canada
-$16K -318 Closed
QT
181
Quantbot Technologies
New York
-$10K -200 Closed
Simplex Trading
182
Simplex Trading
Illinois
-$7.48K -138 Closed

CSTL Hedge Fund Activity: Q4 2020 in Review

163 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2020, worth a combined $1.29B — up 91% from $674M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CSTL positions and 19 closed out — a net gain of 20 holders — while 64 added to existing stakes and 45 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $87.9M. The largest seller was Nexpoint Asset Management, exiting entirely with an estimated $36.4M sold.

  • 163 institutional investors held Castle Biosciences (CSTL) as of Q4 2020, up from 144 in Q3 2020.
  • Funds reported $1.29B of Castle Biosciences stock for Q4 2020, up 91% quarter-over-quarter.
  • 39 funds opened new Castle Biosciences positions in Q4 2020 and 19 closed out, a net change of +20 holders.
  • The largest Castle Biosciences buyer in Q4 2020 was ARK Investment Management, an estimated $87.9M added.
  • The largest Castle Biosciences seller in Q4 2020 was Nexpoint Asset Management, an estimated $36.4M sold.

Based on aggregated 13F filings for Q4 2020.